MRKR vs. STSA, EYEN, APM, CLSD, DMAC, FBLG, SKYE, SCPH, CNTX, and RPTX
Should you be buying Marker Therapeutics stock or one of its competitors? The main competitors of Marker Therapeutics include Satsuma Pharmaceuticals (STSA), Eyenovia (EYEN), Aptorum Group (APM), Clearside Biomedical (CLSD), DiaMedica Therapeutics (DMAC), FibroBiologics (FBLG), Skye Bioscience (SKYE), scPharmaceuticals (SCPH), Context Therapeutics (CNTX), and Repare Therapeutics (RPTX). These companies are all part of the "pharmaceutical preparations" industry.
Marker Therapeutics (NASDAQ:MRKR) and Satsuma Pharmaceuticals (NASDAQ:STSA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, community ranking, valuation, analyst recommendations, media sentiment, profitability and earnings.
22.4% of Marker Therapeutics shares are held by institutional investors. Comparatively, 93.3% of Satsuma Pharmaceuticals shares are held by institutional investors. 17.4% of Marker Therapeutics shares are held by insiders. Comparatively, 31.2% of Satsuma Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
In the previous week, Marker Therapeutics had 2 more articles in the media than Satsuma Pharmaceuticals. MarketBeat recorded 2 mentions for Marker Therapeutics and 0 mentions for Satsuma Pharmaceuticals. Marker Therapeutics' average media sentiment score of 0.50 beat Satsuma Pharmaceuticals' score of 0.00 indicating that Marker Therapeutics is being referred to more favorably in the media.
Marker Therapeutics has higher revenue and earnings than Satsuma Pharmaceuticals.
Marker Therapeutics has a beta of 1.53, meaning that its stock price is 53% more volatile than the S&P 500. Comparatively, Satsuma Pharmaceuticals has a beta of 0.1, meaning that its stock price is 90% less volatile than the S&P 500.
Marker Therapeutics presently has a consensus price target of $11.00, indicating a potential upside of 101.83%. Given Marker Therapeutics' higher possible upside, analysts clearly believe Marker Therapeutics is more favorable than Satsuma Pharmaceuticals.
Marker Therapeutics' return on equity of 0.00% beat Satsuma Pharmaceuticals' return on equity.
Satsuma Pharmaceuticals received 160 more outperform votes than Marker Therapeutics when rated by MarketBeat users. Likewise, 63.46% of users gave Satsuma Pharmaceuticals an outperform vote while only 63.39% of users gave Marker Therapeutics an outperform vote.
Summary
Marker Therapeutics beats Satsuma Pharmaceuticals on 9 of the 13 factors compared between the two stocks.
Get Marker Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for MRKR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MRKR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Marker Therapeutics Competitors List
Related Companies and Tools
Free MRKR Stock Alerts